Efficient Prion Removal from Gonadotropin Solutions by Nanofiltration Membranes - The authors explore whether a nanofiltration process can be effectively leveraged for removal of prions under conditio

ADVERTISEMENT

Efficient Prion Removal from Gonadotropin Solutions by Nanofiltration Membranes
The authors explore whether a nanofiltration process can be effectively leveraged for removal of prions under conditions used for the manufacture of urine-derived gonadotropins.


BioPharm International
Volume 24, Issue 12, pp. 36-49

REFERENCES

1. S.B. Prusiner et al., Cell 93 (3), 337–348 (1998).

2. S.B. Prusiner, Science 216 (4542), 136–144 (1982).

3. H. Büeler et al., Cell 73 (7), 1339–1347 (1993).

4. P. Brown, M.A. Preece, and R.G. Will, Lancet 340 (8810), 24–27 (1992).

5. A.M. Haywood, N. Engl. J. Med. 337 (25), 1821–1828 (1997).

6. A. Aguzzi and M. Polymenidou, Cell 116 (2), 313–327 (2004).

7. A. Aguzzi, Haematologica 85 (1), 3–10 (2000).

8. A. Aguzzi et al., Cell. Mol. Life Sci. 53 (6), 485–495 (1997).

9. A. Van Dorsselaer et al., PLoS One 6 (3), e17815 (2011).

10. H. Seeger et al., Science 310 (5746), 324–326 (2005).

11. R. Matorras and F.J. Rodriguez-Escudero, Hum. Reprod. 18 (5), 1129–1130 (2003).

12. D.M. Taylor, J. Hosp. Infect. 43, S69–S76 (1999).

13. D.M. Taylor, Dev. Biol. Stand. 75, 97–102 (1990).

14. J. Tateishi et al., Biologicals 29, 17–25 (2001).

15. S.R. Petteway et al., Haemophilia 4, 166 (1998).

16. C.F. Gölker et al., Biologicals 24, 103–111 (1996).

17. M. Blum et al., Biopharm Int. 11 (4), 28–34 (1998).

18. J. Tateishi T. Kitamoto, and H. Hiratani, Lancet 2 (8467), 1299–1300 (1985).

19. J. Tateishi et al., Membrane 18, 367–362 (1993).

20. J. Tateishi, et al., "Removal of the Prion Protein Using Validatable Filter," in Animal Cell Technology: Development towards the 21st Century, B.C. Beuvery, W.P. Zeijlemaker, and J.B. Griffiths, Eds. (Kluwer Academic Publishers, The Netherlands, 1995), pp. 637–640.

21. M. Yunoki et al., Biologicals 36 (1), 27–36 (2008).

22. K.J. Gilligan et al., "The Use of Composite Membrane Size Exclusion Filtration to Remove TSE Infectious Particles From a Model Protein Solution," http://www.millipore.com/techpublications/tech1/ps1020en00, accessed Nov. 2011.

23. F. Badmington et al., Pharm. Tech. 19 (9), 64–76 (1995).

24. P. Klohn et al., Proc. Natl. Acad. Sci. USA 100 (20), 11666–11671 (2003).

25. J.A. Edgeworth et al., Proc. Natl. Acad. Sci. USA 106 (9), 3479–3483 (2009).

26. J. Falsig et al., Nat. Neurosci. 11 (1) 109–117 (2008).

27. S.B. Prusiner, Science 252 (5012), 1515–1522 (1991).

28. V. Smirnovas et al., J. Biol. Chem. 284 (36) 24233–24241 (2009).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

J&J Speeds Ebola Vaccine Development and Expands Production
October 24, 2014
Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Manufacturing Challenges of mAb Production: CHO or Plant Cells?
October 24, 2014
Celgene and Sutro Partner on ADC Development
October 24, 2014
GSK Accelerates Ebola Vaccine Development
October 24, 2014
Author Guidelines
Source: BioPharm International,
Click here